Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (ALNY) carries a ŷRobot AI score of 57 out of 100. The model's fair value estimate is $242.96, 4.8% above the last close of $231.83. The chart signal reads Bearish.
| Metric | ALNY |
|---|---|
| AI score | 57 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $242.96 |
| Upside to fair value | 4.8% |
| Previous close | $231.83 |
| P/E | 44.22 |
| Price / sales | 6.44 |
| Market cap | $30.04B |
| EPS | 5.58 |
| Revenue growth | 38.3% |
| 1-year price change | 7.9% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about ALNY
Is ALNY overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates Alnylam Pharmaceuticals Inc (ALNY) at $242.96 against a last close of $231.83, implying 4.8% upside to the model's estimate.
Is ALNY's chart signal bullish or bearish?
The chart-signal model classifies ALNY as Neutral as of Oct 16, 2026, with a signal score of -0.07 on a -1 to 1 scale.
What is ALNY's ŷRobot AI score?
ALNY scores 57 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is ALNY stock expensive on P/E and P/S?
ALNY trades at 44.2 times earnings and 6.4 times sales as of Oct 16, 2026.
What does ALNY's seasonal forecast show?
ŷRobot's seasonal forecast curve for ALNY reads -4.6% at 30 days, -5.7% at 90 days, and +7.9% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ALNY growing?
Alnylam Pharmaceuticals Inc's revenue growth is +38.3% and free-cash-flow growth is -23.6% on the latest reported figures.
ALNY chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.